Open AccessPhase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
Author(s) -
D. Neil Hayes,
Amy S. Lucas,
Tawee Tanvetya,
Monika K. Krzyzanowska,
Christine H. Chung,
Barbara A. Murphy,
Jill Gilbert,
Ranee Mehra,
Dominic T. Moore,
Arif Sheikh,
Janelle M. Hoskins,
Michele C. Hayward,
Ni Zhao,
Wendi O'Connor,
Karen E. Weck,
Roger B. Cohen,
Ezra E.W. Cohen
Publication year - 2012
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/6k9v-5662
Subject(s) - thyroid carcinoma , refractory (planetary science) , follicular phase , medicine , selumetinib , iodine , oncology , endocrinology , thyroid , cancer research , chemistry , biology , cancer , colorectal cancer , organic chemistry , astrobiology , kras
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom